Satya Das, MD, MSCI, on Research Presented at the 2021 ASCO Gastrointestinal Cancer Symposium
The expert in hematology/oncology discussed what research he is most looking forward to seeing the results of at the meeting.
In an interview with CancerNetwork®, Satya Das, MD, MSCI, assistant professor of Medicine in the department of Medicine in the division of Hematology/Oncology at Vanderbilt University Medical Center, spoke about the research he is most excited to see presented at the 2021 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancer Symposium.
Transcription:
I’m a basically a [gastrointestinal] oncologist and I focus on neuroendocrine tumors…and also drug development. I think the things that interest me most pertain to those 2 areas. Particularly with regards to neuroendocrine tumors, I think the role for immunotherapy and the higher-grade neuroendocrine cancers is something that’s still actively being developed. There [are] some interesting data with both [peptide receptor radionuclide therapy; PRRT] outcomes in grade 3 tumors, as well as immunotherapy outcomes.
And then I think the other focus that was quite interesting to me was the overall survival results from the POLO study [NCT02184195], which is what established olaparib [Lynparza] in [patients with] BRCA-mutant [pancreatic] cancer. And actually, though [it’s] now FDA approved, the overall survival was not met between the 2 arms. I think it raises a lot of questions of how we use targeted treatment in [pancreatic] cancer.
Reference:
Golan T, Hammal P, Reni M, et al. Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. J Clin Oncol. 2021;39(suppl 3):378.
